Lessening Organ Dysfunction With VITamin C

• Status: Active, not recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

LOVIT is a multicentre concealed-allocation parallel-group blinded randomized controlled trial to ascertain the effect of high-dose intravenous vitamin C compared to placebo on mortality or persistent organ dysfunction at 28 days in septic intensive care unit patients. Patients with COVID-19 are considered eligible for this study.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Université de Sherbrooke
• Collaborator: Lotte & John Hecht Memorial Foundation
• Treatments: Ascorbic Acid; Vitamins

Criteria

Inclusion Criteria:

1. Admitted to the intensive care unit with proven or suspected infection as the main diagnosis;

2. Currently treated with a continuous IV infusion of vasopressors (norepinephrine, epinephrine, vasopressin, dopamine, phenylephrine).

Exclusion Criteria:

1. > 24 hours of intensive care unit admission;

2. Known Glucose-6-phosphate dehydrogenase (G6PD) deficiency;

3. Pregnancy;

4. Known allergy to vitamin C;

5. Known kidney stones within the past 1 year;

6. Received any intravenous vitamin C during this hospitalization unless incorporated in parenteral nutrition;

7. Expected death or withdrawal of life-sustaining treatments within 48 hours;

8. Previously enrolled in this study;

9. Previously enrolled in a trial with which co-enrolment is not allowed.

The LOVIT trial has broad eligibility criteria and includes patients with a primary diagnosis of sepsis of any cause (including sepsis caused by viral pathogens as COVID-19).